0001209191-22-005876.txt : 20220201 0001209191-22-005876.hdr.sgml : 20220201 20220201160333 ACCESSION NUMBER: 0001209191-22-005876 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220128 FILED AS OF DATE: 20220201 DATE AS OF CHANGE: 20220201 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Cassella James V CENTRAL INDEX KEY: 0001353528 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36310 FILM NUMBER: 22578878 MAIL ADDRESS: STREET 1: 2091 STIERLIN COURT CITY: MOUNTAIN VIEW STATE: CA ZIP: 94043 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CONCERT PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001367920 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 65 HAYDEN AVENUE STREET 2: SUITE 3000N CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 781-860-0045 MAIL ADDRESS: STREET 1: 65 HAYDEN AVENUE STREET 2: SUITE 3000N CITY: LEXINGTON STATE: MA ZIP: 02421 FORMER COMPANY: FORMER CONFORMED NAME: CONCERT PHARMACEUTICALS INC DATE OF NAME CHANGE: 20060628 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-01-28 0 0001367920 CONCERT PHARMACEUTICALS, INC. CNCE 0001353528 Cassella James V C/O CONCERT PHARMACEUTICALS, INC. 65 HAYDEN AVENUE, SUITE 3000N LEXINGTON MA 02421 0 1 0 0 Chief Development Officer Common Stock 2022-01-28 4 A 0 75800 A 158884 D Common Stock 2022-01-28 4 A 0 34700 A 193584 D Represents a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. These RSUs vest in equal annual installments over a three-year period measured from the date of grant. The amount listed represents the maximum number of shares of Common Stock of the Issuer that may be delivered pursuant to the grant. Not applicable. Represents a grant of RSUs. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. These RSUs vest one business day after the date on which the Food and Drug Administration notifies the Issuer that it has accepted for filing a New Drug Application for CTP-543, provided that the date of acceptance is on or before a certain date in 2023. The amount listed represents the maximum number of shares that may be delivered pursuant to the grant. /s/ Jeffrey A. Munsie, attorney-in-fact 2022-02-01